Improved effect of the combination naltrexone/D-penicillamine in the prevention of alcohol relapse-like drinking in rats. (January 2014)

• Record Type: Journal Article
• Authors: Orrico, Alejandro; Martí-Prats, Lucía; Cano-Cebrián, María J; Granero, Luis; Polache, Ana; Zornoza, Teodoro
• Is Part Of: Journal of psychopharmacology. Volume 28:Number 1(2014:Jan.)
• Page Start: 76
• Page End: 81
• Publication Date: 2014-01
• Subjects: D-penicillamine -- naltrexone -- acetaldehyde -- mu-opioid receptor -- ethanol relapse prevention; Psychopharmacology -- Periodicals; 615.78
• DOI: 10.1177/0269881113515063
• Languages: English
• ISSNs: 0269-8811

Abstract

Opioid antagonists are licensed drugs for treating alcohol use disorders; nonetheless, clinical studies have evidenced their limited effectiveness. Preclinical findings indicate that opioid receptor (OR) antagonists, such as naltrexone (NTX), reduce the alcohol deprivation effect (ADE). However, a detailed analysis of published data shows the existence of a delayed increase in ethanol consumption after continuous OR blockade, a phenomenon originally called as 'delayed ADE'. We have recently reported that D-penicillamine (DP) is able to prevent ADE through a mechanism dependent on the inactivation of acetaldehyde, the main metabolite of ethanol. Hypothetically, OR activation would be triggered by acetaldehyde after ethanol consumption. Hence, we conjecture that the combination of NTX and DP, due to their distinct but complementary mechanisms to impede OR activation, may be more efficacious in the prevention of the ADE and, specifically, the 'delayed ADE'. Herein, we compare the effects of the combination NTX/DP (NTX: 2×5 mg/kg SC injection daily/DP: SC infusion (0.25 mg/h)) versus NTX on the ADE in long-term ethanol-experienced rats. As expected, NTX-treated animals displayed a delayed ADE. However, NTX/DP treatment prevented this delayed effect. Our present data indicate that this combination therapy shows an adequate anti-relapse preclinical efficacy being able to overcome the preclinical limitations of NTX alone.